{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:36:37Z","timestamp":1784874997831,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xinjiang Key Laboratory of HIV\/AIDS Prevention and Control Research","award":["XJYS1706"],"award-info":[{"award-number":["XJYS1706"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX10715-007"],"award-info":[{"award-number":["2018ZX10715-007"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Youth science and technology innovation talent of Tianshan Talent Training Program in Xinjiang","award":["2022TSYCCX0099"],"award-info":[{"award-number":["2022TSYCCX0099"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Epidemiol Glob Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The tolerance of inactivated SARS-CoV-2 vaccines in people living with HIV (PLWH) remains unclear. We aimed to evaluate the tolerance of inactivated SARS-CoV-2 vaccines in PLWH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective cohort study recruited 3327 PLWH for questionnaires and laboratory testing. Subjects were screened to ensure they were receiving antiretroviral therapy for PLWH without SARS-CoV-2 infection. Poisson regression analyses were conducted to assess the association between vaccination and HIV viral rebound, estimating absolute risk difference and relative risk (RR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 724 PLWH without SARS-CoV-2 infection participated in this study. No significant increase in HIV viral rebound risk was observed after vaccination in the 1\/2-dose, 3-dose, and 4-dose groups compared to the 0-dose group. The RRs for the 1\/2-dose, 3-dose, and 4-dose groups were 1.22 (95% confidence interval [CI]: 0.55, 2.72), 0.90 (95% CI: 0.48, 1.69), and 1.01 (95% CI: 0.35, 2.89), respectively. Similar results were observed across subgroups. Post-vaccination adverse reactions were minimal, occurring in 2.16% of cases, mostly fatigue and muscle soreness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study suggests that inactivated SARS-CoV-2 vaccines do not adversely affect the risk of HIV viral rebound and were well-tolerated in PLWH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s44197-025-00452-4","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:23:45Z","timestamp":1755163425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tolerance of Inactivated SARS-CoV-2 Vaccine for People Living with HIV: A Real-World Evidence Analysis from a Retrospective Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Qian","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","volume":"4","author":"JM Tesoriero","year":"2021","unstructured":"Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in new York state. JAMA Netw Open. 2021;4:e2037069. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37069.","journal-title":"JAMA Netw Open"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(21)00151-X","volume":"8","author":"W Jassat","year":"2021","unstructured":"Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South africa: a cohort study. Lancet HIV. 2021;8:e554\u201367. https:\/\/doi.org\/10.1016\/S2352-3018(21)00151-X.","journal-title":"Lancet HIV"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11904-022-00618-w","volume":"19","author":"MA Spinelli","year":"2022","unstructured":"Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV\/AIDS Rep. 2022;19:425\u201332. https:\/\/doi.org\/10.1007\/s11904-022-00618-w.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","volume":"9","author":"S Bertagnolio","year":"2022","unstructured":"Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO global clinical platform of COVID-19. Lancet HIV. 2022;9:e486. https:\/\/doi.org\/10.1016\/S2352-3018(22)00097-2.","journal-title":"Lancet HIV"},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"e29395","DOI":"10.1002\/jmv.29395","volume":"96","author":"Y Wang","year":"2024","unstructured":"Wang Y, Lan X, Qiao Y, Huo Y, Wang L, Liang S, et al. Safety and immunogenicity of homologous prime-boost coronavac vaccine in people living with HIV in china: A multicenter prospective cohort study. J Med Virol. 2024;96:e29395. https:\/\/doi.org\/10.1002\/jmv.29395.","journal-title":"J Med Virol"},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30:154. https:\/\/doi.org\/10.1016\/j.chom.2022.01.005.","journal-title":"Cell Host Microbe"},{"key":"452_CR7","unstructured":"World Health Organization. Coronavirus disease (COVID-19) and people living with HIV n.d. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-covid-19-and-people-living-with-hiv (accessed November 12, 2024)."},{"key":"452_CR8","unstructured":"National Institutes of Health. HIV and, COVID-19 |. NIH 2024. https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-and-covid-19 (accessed August 20, 2024)."},{"key":"452_CR9","doi-asserted-by":"publisher","unstructured":"K N, L-C A, G E, G A, P E. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6. https:\/\/doi.org\/10.1038\/s41541-021-00292-w.","DOI":"10.1038\/s41541-021-00292-w"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/v17020171","volume":"17","author":"N Xu","year":"2025","unstructured":"Xu N, Shen Y, Huang W, Nie J. The current status in terms of vaccination for individuals infected with human immunodeficiency virus. Viruses. 2025;17:171. https:\/\/doi.org\/10.3390\/v17020171.","journal-title":"Viruses"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijid.2022.10.005","volume":"124","author":"J Yin","year":"2022","unstructured":"Yin J, Chen Y, Li Y, Wang C, Zhang X. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. Int J Infect Dis. 2022;124:212\u201323. https:\/\/doi.org\/10.1016\/j.ijid.2022.10.005.","journal-title":"Int J Infect Dis"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2352-3018(21)00278-2","volume":"8","author":"TL Hiv","year":"2021","unstructured":"Hiv TL. Prioritise people with HIV for COVID-19 vaccination. Lancet HIV. 2021;8:e659. https:\/\/doi.org\/10.1016\/S2352-3018(21)00278-2.","journal-title":"Lancet HIV"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21:39\u201351. https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8.","journal-title":"Lancet Infect Dis"},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","volume":"22","author":"S Xia","year":"2022","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial. Lancet Infect Dis. 2022;22:196\u2013208. https:\/\/doi.org\/10.1016\/S1473-3099(21)00462-X.","journal-title":"Lancet Infect Dis"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"e227038","DOI":"10.1001\/jamanetworkopen.2022.7038","volume":"5","author":"MJM Niesen","year":"2022","unstructured":"Niesen MJM, Pawlowski C, O\u2019Horo JC, Challener DW, Silvert E, Donadio G, et al. Surveillance of safety of 3 doses of COVID-19 mRNA vaccination using electronic health records. JAMA Netw Open. 2022;5:e227038. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7038.","journal-title":"JAMA Netw Open"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/vaccines10030424","volume":"10","author":"R Shrestha","year":"2022","unstructured":"Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, et al. COVID-19 vaccine hesitancy and associated factors among people with HIV in the united states: findings from a National survey. Vaccines (Basel). 2022;10:424. https:\/\/doi.org\/10.3390\/vaccines10030424.","journal-title":"Vaccines (Basel)"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"e33995","DOI":"10.2196\/33995","volume":"8","author":"Y Yao","year":"2022","unstructured":"Yao Y, Chai R, Yang J, Zhang X, Huang X, Yu M, et al. Reasons for COVID-19 vaccine hesitancy among Chinese people living with HIV\/AIDS: structural equation modeling analysis. JMIR Public Health Surveillance. 2022;8:e33995. https:\/\/doi.org\/10.2196\/33995.","journal-title":"JMIR Public Health Surveillance"},{"key":"452_CR18","unstructured":"World Health Organization. The role of HIV viral suppression in improving individual health and reducing transmission 2023. https:\/\/www.who.int\/publications-detail-redirect\/9789240055179 (accessed May 25, 2024)."},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.chom.2019.08.003","volume":"26","author":"M-A De Scheerder","year":"2019","unstructured":"De Scheerder M-A, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe. 2019;26:347\u2013e3587. https:\/\/doi.org\/10.1016\/j.chom.2019.08.003.","journal-title":"Cell Host Microbe"},{"key":"452_CR20","doi-asserted-by":"publisher","unstructured":"Lv X, Zhao C, Song B, Huang H, Song S, Long H et al. COVID-19 vaccination in people living with HIV and AIDS (PLWHA) in china: A cross-sectional study. Hum Vaccin Immunother N D;19:2151798. https:\/\/doi.org\/10.1080\/21645515.2022.2151798","DOI":"10.1080\/21645515.2022.2151798"},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/vaccines12010044","volume":"12","author":"DK Nomah","year":"2023","unstructured":"Nomah DK, Reyes-Urue\u00f1a J, Alonso L, D\u00edaz Y, Moreno-Forn\u00e9s S, Aceiton J, et al. Comparative analysis of primary and monovalent booster SARS-CoV-2 vaccination coverage in adults with and without HIV in Catalonia. Spain Vaccines. 2023;12:44. https:\/\/doi.org\/10.3390\/vaccines12010044.","journal-title":"Spain Vaccines"},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41562-023-01733-3","volume":"8","author":"SK Sulaiman","year":"2024","unstructured":"Sulaiman SK, Musa MS, Tsiga-Ahmed FI, Sulaiman AK, Bako AT. A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV. Nat Hum Behav. 2024;8:100. https:\/\/doi.org\/10.1038\/s41562-023-01733-3.","journal-title":"Nat Hum Behav"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"107915","DOI":"10.1016\/j.isci.2023.107915","volume":"26","author":"VA Matveev","year":"2023","unstructured":"Matveev VA, Mihelic EZ, Benko E, Budylowski P, Grocott S, Lee T, et al. Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. iScience. 2023;26:107915. https:\/\/doi.org\/10.1016\/j.isci.2023.107915.","journal-title":"iScience"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"883453","DOI":"10.3389\/fpubh.2022.883453","volume":"10","author":"S Wu","year":"2022","unstructured":"Wu S, Ming F, Xing Z, Zhang Z, Zhu S, Guo W, et al. COVID-19 vaccination willingness among people living with HIV in wuhan, China. Front Public Health. 2022;10:883453. https:\/\/doi.org\/10.3389\/fpubh.2022.883453.","journal-title":"Front Public Health"},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/vaccines9090951","volume":"9","author":"JP Aguilar Ticona","year":"2021","unstructured":"Aguilar Ticona JP, Nery N, Victoriano R, Fofana MO, Ribeiro GS, Giorgi E, et al. Willingness to get the COVID-19 vaccine among residents of slum settlements. Vaccines (Basel). 2021;9:951. https:\/\/doi.org\/10.3390\/vaccines9090951.","journal-title":"Vaccines (Basel)"},{"key":"452_CR26","doi-asserted-by":"publisher","unstructured":"Zhao H, Wang H, Li H, Zheng W, Yuan T, Feng A et al. Uptake and adverse reactions of COVID-19 vaccination among people living with HIV in china: a case\u2013control study. Hum Vaccin Immunother N D 2021;17:4964\u201370. https:\/\/doi.org\/10.1080\/21645515.2021.1991183","DOI":"10.1080\/21645515.2021.1991183"},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","volume":"9","author":"KM Kunisaki","year":"2009","unstructured":"Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493\u2013504. https:\/\/doi.org\/10.1016\/S1473-3099(09)70175-6.","journal-title":"Lancet Infect Dis"},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/QAD.0000000000003579","volume":"37","author":"DW Griffin","year":"2023","unstructured":"Griffin DW, Mangalore RP, Hoy JF, McMahon JH. Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV. AIDS. 2023;37:1345. https:\/\/doi.org\/10.1097\/QAD.0000000000003579.","journal-title":"AIDS"},{"key":"452_CR29","doi-asserted-by":"publisher","first-page":"e29334","DOI":"10.1002\/jmv.29334","volume":"95","author":"J Li","year":"2023","unstructured":"Li J, Nie L, Guo C, Deng Y, Guo Q, Pang C, et al. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study. J Med Virol. 2023;95:e29334. https:\/\/doi.org\/10.1002\/jmv.29334.","journal-title":"J Med Virol"},{"key":"452_CR30","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","volume":"8","author":"J Frater","year":"2021","unstructured":"Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial. Lancet HIV. 2021;8:e474. https:\/\/doi.org\/10.1016\/S2352-3018(21)00103-X.","journal-title":"Lancet HIV"},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","volume":"8","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial. Lancet HIV. 2021;8:e568. https:\/\/doi.org\/10.1016\/S2352-3018(21)00157-0.","journal-title":"Lancet HIV"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/QAD.0000000000003841","volume":"38","author":"MC Duncan","year":"2024","unstructured":"Duncan MC, Omondi FH, Kinloch NN, Lapointe HR, Speckmaier S, Moran-Garcia N, et al. Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size. AIDS. 2024;38:1120\u201330. https:\/\/doi.org\/10.1097\/QAD.0000000000003841.","journal-title":"AIDS"},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijid.2021.08.039","volume":"117","author":"C Gong","year":"2022","unstructured":"Gong C, Song X, Li X, Lu L, Li T. Immunological changes after COVID-19 vaccination in an HIV-positive patient. Int J Infect Dis. 2022;117:230\u20132. https:\/\/doi.org\/10.1016\/j.ijid.2021.08.039.","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Epidemiology and Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-025-00452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44197-025-00452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-025-00452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:04:06Z","timestamp":1755252246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44197-025-00452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s44197-025-00452-4","relation":{},"ISSN":["2210-6014"],"issn-type":[{"value":"2210-6014","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention (Ethics Approval No. 2021-005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"106"}}